| Product Information |
|
| Registration Number |
BR-1388
|
| Generic Name |
Meningococcal Group A, C, W-135 and Y Conjugate
Vaccine
|
| Brand Name |
Menquadfi
|
| Dosage Strength |
Formulation: Each dose (0.5 mL) contains: Neisseria meningitidis group A polysaccharide* .... 10 mcg Neisseria meningitidis group C polysaccharide* .... 10 mcg Neisseria meningitidis group Y polysaccharide* .... 10 mcg Neisseria meningitidis group W-135 polysaccharide* .... 10 mcg *Conjugated to Tetanus Toxoid carrier protein... 55 mcg** **Tetanus Toxoid quantity is approximate and dependent on the polysaccharide to protein ratio for the conjugates in each formulation
|
| Dosage Form |
Solution for Injection (IM)
|
| Classification |
Prescription Drug (RX)
|
| Packaging |
Single dose. 0.5 mL in 2 mL USP Type I glass vial with gray chlorobutyl rubber stopper sealed with aluminum and black plastic flip-off cap (Box of 1's and 5's)
|
| Pharmacologic Category |
-
|
| Manufacturer |
Sanofi Pasteur
|
| Country of Origin |
United States of America
|
| Trader |
N/A
|
| Importer |
Sanofi Pasteur, Inc.
|
| Distributor |
Zuellig Pharma Corporation
|
| Application Type |
Monitored Release
|
| Issuance Date |
04 March 2022
|
| Expiry Date |
04 March 2027
|